Pronzato P, Vigani A, Pensa F, Vanoli M, Tani F, Vaira F
U.O. Oncologia Medica, Ospedale S. Andrea, La Spezia, Italy.
Am J Clin Oncol. 1997 Oct;20(5):519-21. doi: 10.1097/00000421-199710000-00018.
We have carried out a phase II study in advanced or metastatic transitional cell carcinoma of the bladder. Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy. Treatment consisted of ifosfamide 1000 mg/sm in a 2-hour infusion for 5 consecutive days from d.1 to d.5. Mesna was administered intravenously at a 20% of the ifosfamide dosage before ifosfamide and orally at 40% after 4 and 8 hours from the ifosfamide infusion. Twenty patients entered the study and received a total of 62 cycles: the treatment resulted feasible on an outpatient basis, with mild toxicity. Only one partial response was observed. With this dose and schedule, ifosfamide appeared less effective than in a previous report at higher doses. Toxicity was acceptable.
我们开展了一项针对晚期或转移性膀胱移行细胞癌的II期研究。符合条件的患者患有无法切除的膀胱癌，此前接受过一线全身化疗。治疗方案为异环磷酰胺1000mg/m²，在第1天至第5天连续5天进行2小时静脉输注。美司钠在异环磷酰胺输注前以异环磷酰胺剂量的20%静脉给药，在异环磷酰胺输注后4小时和8小时分别以40%的剂量口服给药。20名患者进入研究，共接受了62个周期的治疗：该治疗方案在门诊可行，毒性轻微。仅观察到1例部分缓解。采用此剂量和方案时，异环磷酰胺似乎比之前更高剂量报告中的效果要差。毒性是可接受的。
